We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The HHS’ Office of Inspector General (OIG) is focusing on ways the federal government can reduce the amount it spends for prescription drugs under Medicaid, including greater use of generics, a high-ranking OIG official says.
All “unanticipated problems” affecting participants in clinical trials sponsored or supported by the U.S. Department of Health and Human Services must be reported, a new guidance from the Office for Human Research Protections (OHRP) says.
The Centers for Medicare & Medicaid Services (CMS) must strengthen its guidance regarding an exception to Medicaid price-reporting requirements to prevent drug companies’ abuse of that provision, key lawmakers say.
HHS’ Agency for Healthcare Research and Quality (AHRQ) found the most commonly prescribed antidepressants are similar in effectiveness, but have varying side effects, according to a new report.
All “unanticipated problems” affecting participants in clinical trials sponsored or supported by HHS must be reported, a new guidance from the Office for Human Research Protections (OHRP) says.
An analysis of 84 studies by HHS’ Agency for Healthcare Research and Quality (AHRQ) found no strong evidence that atypical antipsychotics are effective for many of the off-label uses for which they are commonly prescribed.